KR20210057113A - 항-trem-2 작용제 항체 - Google Patents
항-trem-2 작용제 항체 Download PDFInfo
- Publication number
- KR20210057113A KR20210057113A KR1020217010551A KR20217010551A KR20210057113A KR 20210057113 A KR20210057113 A KR 20210057113A KR 1020217010551 A KR1020217010551 A KR 1020217010551A KR 20217010551 A KR20217010551 A KR 20217010551A KR 20210057113 A KR20210057113 A KR 20210057113A
- Authority
- KR
- South Korea
- Prior art keywords
- seq
- variable region
- antibody
- chain variable
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862729458P | 2018-09-11 | 2018-09-11 | |
| US62/729,458 | 2018-09-11 | ||
| PCT/US2019/050575 WO2020055975A1 (en) | 2018-09-11 | 2019-09-11 | Anti-trem-2 agonist antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20210057113A true KR20210057113A (ko) | 2021-05-20 |
Family
ID=69777153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217010551A Withdrawn KR20210057113A (ko) | 2018-09-11 | 2019-09-11 | 항-trem-2 작용제 항체 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12145988B2 (https=) |
| EP (1) | EP3849598A4 (https=) |
| JP (1) | JP2022500081A (https=) |
| KR (1) | KR20210057113A (https=) |
| CN (1) | CN113164572A (https=) |
| AU (1) | AU2019339452A1 (https=) |
| BR (1) | BR112021004316A2 (https=) |
| CA (1) | CA3111569A1 (https=) |
| IL (1) | IL281201A (https=) |
| MX (1) | MX2021002616A (https=) |
| SG (1) | SG11202102162RA (https=) |
| WO (1) | WO2020055975A1 (https=) |
| ZA (1) | ZA202101537B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| CA3111569A1 (en) | 2018-09-11 | 2020-03-19 | Washington University | Anti-trem-2 agonist antibodies |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| BR112021015656A2 (pt) | 2019-02-20 | 2021-10-05 | Denali Therapeutics Inc. | Anticorpos anti-trem2 e métodos de uso dos mesmos |
| JP2023512450A (ja) | 2020-01-13 | 2023-03-27 | デナリ セラピューティクス インコーポレイテッド | 抗ｔｒｅｍ２抗体及びその使用方法 |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| WO2023192282A1 (en) * | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Methods for treating brain glucose hypometabolism |
| CA3254085A1 (en) * | 2022-05-18 | 2023-11-23 | The Brigham And Women's Hospital, Inc. | KLRB1 LIAISON AGENTS AND THEIR METHODS OF USE |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| JP2025529287A (ja) | 2022-09-06 | 2025-09-04 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | マルファン症候群の処置のためのｔｒｅｍ－２アゴニスト |
| WO2024160736A1 (en) * | 2023-01-30 | 2024-08-08 | Isar Bioscience Gmbh | Human anti-trem2 antibody for treating neurodegenerative disorders |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US20150140672A1 (en) | 2011-12-19 | 2015-05-21 | Washington University | Methods for detecting amyloid beta amyloidosis |
| AU2012359020B2 (en) | 2011-12-19 | 2017-04-13 | The Washington University | Methods for diagnosing Alzheimer's disease |
| EP2923209A4 (en) | 2012-11-20 | 2016-04-27 | Univ Washington | METHOD FOR THE DIAGNOSIS OF DISEASES BY ANALYSIS OF AMYLOID BETA ENRICHMENT KINETICS |
| WO2015116753A1 (en) * | 2014-01-29 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Antibodies against the muc1-c/extracellular domain (muc1-c/ecd) |
| CA2955086A1 (en) | 2014-08-08 | 2016-02-11 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| WO2016064895A1 (en) * | 2014-10-20 | 2016-04-28 | The Brigham And Women's Hospital, Inc. | Targeting apolipoprotein e (apoe) in neurologic disease |
| WO2017058866A1 (en) * | 2015-09-28 | 2017-04-06 | Precision Immune, Inc. | Anti-trem2 antibodies and uses thereof |
| US20190330335A1 (en) * | 2015-10-06 | 2019-10-31 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| CN109641961A (zh) * | 2016-07-22 | 2019-04-16 | 德国神经退行性疾病研究中心 | Trem2切割调节剂及其用途 |
| CA3111569A1 (en) | 2018-09-11 | 2020-03-19 | Washington University | Anti-trem-2 agonist antibodies |
-
2019
- 2019-09-11 CA CA3111569A patent/CA3111569A1/en active Pending
- 2019-09-11 WO PCT/US2019/050575 patent/WO2020055975A1/en not_active Ceased
- 2019-09-11 JP JP2021538178A patent/JP2022500081A/ja active Pending
- 2019-09-11 SG SG11202102162RA patent/SG11202102162RA/en unknown
- 2019-09-11 EP EP19860614.7A patent/EP3849598A4/en not_active Withdrawn
- 2019-09-11 BR BR112021004316A patent/BR112021004316A2/pt not_active Application Discontinuation
- 2019-09-11 AU AU2019339452A patent/AU2019339452A1/en not_active Abandoned
- 2019-09-11 KR KR1020217010551A patent/KR20210057113A/ko not_active Withdrawn
- 2019-09-11 MX MX2021002616A patent/MX2021002616A/es unknown
- 2019-09-11 CN CN201980074318.5A patent/CN113164572A/zh active Pending
- 2019-09-11 US US17/275,092 patent/US12145988B2/en active Active
-
2021
- 2021-03-02 IL IL281201A patent/IL281201A/en unknown
- 2021-03-05 ZA ZA2021/01537A patent/ZA202101537B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021004316A2 (pt) | 2021-11-03 |
| JP2022500081A (ja) | 2022-01-04 |
| CA3111569A1 (en) | 2020-03-19 |
| MX2021002616A (es) | 2021-05-12 |
| ZA202101537B (en) | 2022-07-27 |
| US12145988B2 (en) | 2024-11-19 |
| EP3849598A4 (en) | 2022-07-06 |
| CN113164572A (zh) | 2021-07-23 |
| IL281201A (en) | 2021-04-29 |
| AU2019339452A1 (en) | 2021-03-25 |
| EP3849598A1 (en) | 2021-07-21 |
| US20210284727A1 (en) | 2021-09-16 |
| SG11202102162RA (en) | 2021-04-29 |
| WO2020055975A1 (en) | 2020-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12145988B2 (en) | Anti-TREM-2 agonist antibodies | |
| US12540175B2 (en) | Anti-ApoE antibodies | |
| JP2021191763A (ja) | シヌクレイノパチーの治療のための薬剤、使用および方法 | |
| JP7204235B2 (ja) | 活性型α－シヌクレインに結合する抗体 | |
| CN104602708B (zh) | 痴呆症治疗药或预防药 | |
| JP2021151253A (ja) | 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用 | |
| JP2022023096A (ja) | 過リン酸化タウに特異的な抗体およびその使用方法 | |
| ES2800827T3 (es) | Procedimientos de tratamiento de una tauopatía | |
| KR20150127570A (ko) | 항-Aβ 항체를 이용하여 뇌 아밀로이드 플락을 감소시키는 방법 | |
| US20210324110A1 (en) | Specific murine and humanized monoclonal antibodies detecting pathology associated secondary structure changes in proteins and peptides | |
| JP2021528092A (ja) | インフラマソームに関連する疾患又は病態を治療するための組成物及び方法 | |
| CN116348487A (zh) | 抗淀粉样β抗体 | |
| CN105518024A (zh) | 人抗il-32抗体 | |
| JP2022528459A (ja) | 融合構築物及びその使用 | |
| JP2026504928A (ja) | Ｌｉｌｒｂ４／ｉｌｔ３アンタゴニスト組成物およびその使用方法 | |
| KR20260047599A (ko) | 신경 변성 질환의 치료제 | |
| CN119730880A (zh) | 肌萎缩侧索硬化症、帕金森病、亨廷顿病、脊髓小脑性共济失调、与老化有关的变性疾病或神经疾病、脑老化、或者伴有脑老化的疾病的预防剂或治疗剂 | |
| CN118284626A (zh) | Trem2抗原结合蛋白及其用途 | |
| JP2019503355A (ja) | ＣＤ１１ｂ／ＣＤ１８に対するＣＦＨの結合を阻害する薬剤、およびその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20210409 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |